However, even after accounting for age of onset and other potential cofounding factors like APOE ɛ4 status, we still observed that post‐200 carriers presented with more severe clinical dementia ratings and MMSE scores and tended to show worse cognitive composite scores in later disease stages compared to pre‐200. This evidence concerns the gene APOE and dementia.